Samaritan Biologics LLC – Trademark Portfolio

Entity Type: 16

Samaritan Biologics LLC holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 37 (Building & Construction) across 4 Nice Classification classes. Currently, 0 trademarks are registered and 5 are pending. The owner is based in Cordova, TN.

241 Germantown Bend Cove

Cordova, TN 38018

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Samaritan Biologics LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

37
Building & Construction (2 filings)

Building construction; repair; installation services

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Samaritan Biologics LLC have?

Samaritan Biologics LLC has 7 U.S. trademarks filed with the USPTO. Of these, 5 pending, 2 abandoned.

What trademark classes does Samaritan Biologics LLC file in?

Samaritan Biologics LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 37 (Building & Construction), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is Samaritan Biologics LLC's trademark registration success rate?

Samaritan Biologics LLC has a 0% trademark registration rate, with 0 out of 2 resolved applications resulting in successful registration. Currently, 5 applications are pending review.